Online citations, reference lists, and bibliographies.
← Back to Search

Inhibitors Of The Endocannabinoid-degrading Enzymes, Or How To Increase Endocannabinoid's Activity By Preventing Their Hydrolysis.

Marion Feledziak, D. Lambert, J. Marchand-Brynaert, G. Muccioli
Published 2012 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Endocannabinoids are lipid transmitters binding and activating the cannabinoid receptors. Both cannabinoid receptors and endocannabinoids, such as 2-arachidonoylglycerol and anandamide, have been shown to control numerous physiological and pathological processes, including in the central nervous system. Thus regulating endocannabinoid levels in-vivo represents an interesting therapeutic perspective in several CNS-related diseases. To date four enzymes - Fatty Acid Amide Hydrolase (FAAH), N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA), Monoacylglycerol Lipase (MAGL), α/β-Hydrolase Domain 6 (ABHD6) - were shown to control endocannabinoid levels in tissues or in intact cells. While the searches for NAAA and ABHD6 inhibitors are still in their beginning, a growing number of selective and potent inhibitors are now available to inhibit FAAH and MAGL activities. Here, based on the literature and patent literature, we review the compounds of the different chemical families that have been developed to inhibit these enzymes, with a special emphasis on FAAH and MAGL inhibitors.
This paper references
Preparation of pyridyl non-aromatic nitrogenated heterocyclic-1carboxylate ester derivatives as FAAH inhibitors
T. Ishii (2006)
10.1016/j.expneurol.2010.03.018
The endocannabinoid system and psychiatric disorders
D. Parolaro (2010)
Preparation of piperidinecarboxamides and piperazinecarboxamides as fatty acid amide hydrolase (FAAH) inhibitors
T. Matsumoto (2006)
10.1074/jbc.M800524200
Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation*
J. Zhang (2008)
10.1021/BI701378G
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
K. Ahn (2007)
10.1002/cmdc.200500017
Synthesis and Structure–Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring
G. Tarzia (2006)
10.1002/CHIN.199227248
Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α-Ketobenzoxazoles, and the X- Ray Crystal Structure of the Covalent Complex Between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole.
P. D. Edwards (1992)
International review of neurobiology . G . Bagetta , M . T . Corasaniti , T . Sakurada , and S
S Gaetani
10.1124/jpet.109.155465
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
S. Kinsey (2009)
Preparation of oxazolyl piperidinyl methanones as modulators of fatty acid amide hydrolase
R. Apodaca (2007)
10.1002/CBDV.200790157
Fatty Acid Amide Hydrolase: From Characterization to Therapeutics
G. Labar (2007)
Combination FAAH inhibitor and analgesic, antiinflammatory or anti-pyretic agent
O. Dasse (2008)
Purification and some properties of a monoacylglycerol-hydrolyzing enzyme of rat adipose tissue.
H. Tornqvist (1976)
Preparation of heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase inhibitors
G. J. Breitenbucher (2010)
10.1073/pnas.1011663107
Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening
D. Bachovchin (2010)
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
P. B. Smith (1994)
10.2174/0929867023370707
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
D. Lambert (2002)
Alkylcarbamic acid esters as inhibitors of fatty acid amide hydrolase
D. Putman (2008)
10.1097/00000441-196606000-00014
International Review of Neurobiology, Vol. 8
Es (1966)
10.1021/tx1002194
Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2.
S. Xie (2010)
Crystal structure and alternative crystal form of human monoacylglycerol lipase (MGLL), and use for design and screening of MGLL inhibitors
C. Schubert (2010)
10.1002/CHIN.200330264
Boronic Acid Compounds as Potential Pharmaceutical Agents
Wenqian Yang (2003)
Preparation of pyrimidine derivatives
W·哥伦格 (1997)
10.1002/cbic.200900621
Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling
G. Labar (2010)
10.1021/jm801051t
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
Anna Minkkilae (2008)
Inhibitors of the Endocannabinoid-Degrading Enzymes
M. L. Behnke (2012)
10.1016/S0304-3959(98)00041-4
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
S. Jaggar (1998)
10.1021/JM00020A011
Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles.
P. D. Edwards (1995)
Isoxazolines as inhibitors of fatty acid amide hydrolase
M. L. Behnke (2011)
10.1016/j.jmb.2010.05.034
Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation.
Mauro Mileni (2010)
10.1016/J.BBALIP.2005.08.010
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages.
Yong-Xin Sun (2005)
Preparation of heteroaryl-substituted urea modulators of fatty acid amide hydrolase
J. G. Breitenbucher (2010)
Preparation of heterocyclic phenyl carbamates as novel FAAH inhibitors
M. Myllymaeki (2008)
10.1016/j.neuropharm.2004.12.017
A second N-acylethanolamine hydrolase in mammalian tissues
N. Ueda (2005)
10.1074/jbc.M110.202853
Dual Inhibition of α/β-Hydrolase Domain 6 and Fatty Acid Amide Hydrolase Increases Endocannabinoid Levels in Neurons*
William R. Marrs (2011)
10.1186/1471-2091-10-14
The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways
H. Bradshaw (2009)
Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
S Mazzari (1996)
10.1042/BJ20031695
N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.
K. Tsuboi (2004)
10.1016/j.drudis.2010.03.007
Endocannabinoid biosynthesis and inactivation, from simple to complex.
G. Muccioli (2010)
10.1016/J.NBD.2005.11.004
The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines
D. Panikashvili (2006)
10.1074/jbc.272.43.27218
cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase
M. Karlsson (1997)
10.1002/pro.596
Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution
C. Schalk-Hihi (2011)
10.1038/nature01921
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
J. Fu (2003)
Preparation of indolylalkanoates as modulators of CRTH2, COX-1, COX-2, CD11B, TXA2, DAO, DP1, and/or FAAH
W. Bartolini (2007)
Preparation of piperazine-1-carboxamide and piperidine-1-carboxamide derivatives as inhibitors of fatty acid amide hydrolase (FAAH)
T. Ishii (2008)
10.1016/j.tips.2009.06.006
The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
M. Hill (2009)
10.1074/JBC.M413473200
Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase*
K. Tsuboi (2005)
10.1111/j.1476-5381.2009.00276.x
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone‐based enzyme inhibitors
A. King (2009)
Preparation of oxazole derivatives as fatty acid amide hydrolase inhibitors
D. L. Boger (2008)
10.1016/j.ejmech.2010.04.040
Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors.
Frédéric De Wael (2010)
10.1016/J.BBALIP.2007.03.005
Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies.
K. Tsuboi (2007)
10.1038/nchembio.129
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
J. Z. Long (2009)
10.1016/j.jmb.2009.11.060
Structural basis for human monoglyceride lipase inhibition.
T. Bertrand (2010)
10.1124/jpet.111.180257
Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn (2011)
Azetidinyl diamides as monoacylglycerol lipase inhibitors
H. Bian (2010)
10.1016/j.chembiol.2009.02.013
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.
Kay Ahn (2009)
Alkyl, alkenyl and alkynyl carbamate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Almario-Garcia (2006)
10.1021/JA073650C
A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases.
W. Li (2007)
10.2174/092986710791859414
A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling.
G. Labar (2010)
10.1194/jlr.M012153
An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase[S]
J. Z. Long (2011)
10.1016/S0960-894X(98)00073-0
An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase.
M. Patricelli (1998)
Preparation of oxazole derivatives as inhibitors of FAAH
H. Chobanian (2010)
10.1021/JA00031A046
Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole
P. D. Edwards (1992)
6,7-Dihydro-5Hpyrrolo[3,4-d]pyrimidin-4-yl(quinolin-3-yl)amine derivatives as FAAH modulators and their preparation and use for the treatment of diseases
M. Duncton (2010)
10.1038/28393
Control of pain initiation by endogenous cannabinoids
A. Calignano (1998)
10.1038/nature03658
An endocannabinoid mechanism for stress-induced analgesia
A. Hohmann (2005)
10.1096/fj.10-176602
Increasing endogenous 2‐arachidonoylglycerol levels counteracts colitis and related systemic inflammation
Mireille Alhouayek (2011)
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules.
D. Boger (1998)
10.1124/MOL.104.006353
The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide
J. Lo Verme (2005)
10.1016/j.bcp.2009.04.024
N-acylethanolamines, anandamide and food intake.
H. Hansen (2009)
10.1016/J.CHEMBIOL.2005.04.013
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes.
S. Saario (2005)
Preparation of N-heteroaryloxadiazolone derivatives for use as FAAH inhibitors
D. A. Learmonth (2010)
10.1021/JM0209679
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
S. Vandevoorde (2003)
10.1016/0014-2999(96)00015-5
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
S. Mazzari (1996)
10.1126/SCIENCE.1076535
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
M. Bracey (2002)
10.1016/j.plefa.2009.05.026
The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine.
S. Hu (2009)
10.1016/j.cell.2009.11.027
Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis
Daniel K. Nomura (2010)
5-O-Substituted 3-N-aryl- 1,3,4-oxadiazolone derivatives as FAAH inhibitors and their preparation and use for the treatment of diseases
D. A. Learmonth (2010)
Cyclopenta [ c ] pyrrolylalkylcarbamate derivatives of 5 - membered heterocycles , their preparation and use as fatty acid amido hydrolase ( FAAH ) inhibitors for treating FAAH - related pathologies
A. Abouabdellah (2010)
Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
R. Apodaca (2006)
10.1038/nn.2601
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors
William R. Marrs (2010)
Tetracyclic compounds as inhibitors of fatty acid amide hydrolase and their preparation, pharmaceutical compositions and use in the treatment of diseases
D. L. Boger (2008)
10.1021/JM00001A013
Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency.
P. D. Edwards (1995)
10.1046/j.1528-1157.2001.41499.x
Anticonvulsant Activity of N‐Palmitoylethanolamide, a Putative Endocannabinoid, in Mice
D. Lambert (2001)
10.2174/156802608783498005
Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
S. Vandevoorde (2008)
Preparation of oxooxetanes and related compounds as NAAA (Nacylethanolamine-hydrolyzing acid amidase) inhibitors
D. Piomelli (2009)
10.1021/jm100582w
Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors.
C. Solórzano (2010)
Preparation of benzylpyrrolyloxoacetamide derivatives for use as FAAH inhibitors
K. Sprott (2011)
Partial purification of monoglyceride lipase from adipose tissue.
F. P. Kupiecki (1966)
10.1016/j.chembiol.2009.05.009
Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism.
J. Z. Long (2009)
10.1073/pnas.0907417106
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation
C. Solórzano (2009)
10.1111/j.1440-1681.2008.05081.x
ANTINOCICEPTIVE INTERACTIONS BETWEEN ANANDAMIDE AND ENDOMORPHIN‐1 AT THE SPINAL LEVEL
G. Tuboly (2009)
10.1002/cmdc.200900210
A Second Generation of Carbamate‐Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo
Jason R. Clapper (2009)
10.1073/pnas.152334899
Brain monoglyceride lipase participating in endocannabinoid inactivation
T. V. Dinh (2002)
10.1124/PR.58.3.2
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
P. Pacher (2006)
10.1016/j.pbb.2010.12.002
Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay
S. Kinsey (2011)
10.1021/jm901323s
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
C. N. Kapanda (2009)
The complications of promiscuity: endocannabinoid action and metabolism
Alexander SPH (2007)
10.1038/nn.2632
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Jason R. Clapper (2010)
10.1124/JPET.104.069401
Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity
A. Lichtman (2004)
Preparation of indoleacetates as modulators of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2), cyclooxygenase-2 (COX-2) and fatty acid amide hydrolase (FAAH)
W. Bartolini (2006)
Preparation of 1-Oxa-8azaspiro[4,5]decane-8-carboxamide compounds as FAAH inhibitors for therapy
S. A. Long (2010)
Alkylcarbamic acid ester inhibitors of fatty acid amide hydrolase, and therapeutic use
O. Dasse (2007)
Membered heterocyclyl)alkyl cyclopenta[c]pyrrolylalkylcarboxylate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Abouabdellah (2010)
10.1111/j.1476-5381.2011.01644.x
Inhibiting fatty acid amide hydrolase normalizes endotoxin‐induced enhanced gastrointestinal motility in mice
M. Bashashati (2012)
10.1038/sj.bjp.0707433
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
M. Jhaveri (2007)
10.1126/science.1209200
Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Daniel K. Nomura (2011)
10.1021/JM031140X
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
M. Mor (2004)
10.1021/BI991876P
Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism.
M. Patricelli (1999)
10.1006/BBRC.1997.7431
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells.
T. Bisogno (1997)
Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
K. M. Chevalier (2010)
Preparation of piperazinecarboxamide derivative as fatty acid amide hydrolase modulator
N. A. Hawryluk (2011)
Preparation of arylboronates as inhibitors of fatty acid amide hydrolase
J. Adams (2008)
10.1073/PNAS.94.6.2238
Molecular characterization of human and mouse fatty acid amide hydrolases.
D. Giang (1997)
10.1021/ja902694n
Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.
Mauro Mileni (2009)
10.1016/J.CHEMBIOL.2005.08.011
Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.
J. Alexander (2005)
10.1038/nn.2616
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
J. Schlosburg (2010)
10.1038/35097089
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
D. Panikashvili (2001)
10.1021/jm9016976
Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases.
J. Z. Long (2010)
Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors
M. L. Behnke (2009)
5-O-Substituted 3-N-phenyl-1,3,4-oxadiazolones as FAAH inhibitors and their preparation and use in the treatment of diseases
D. A. Learmonth (2009)
Synthesis of COX-2 and FAAH inhibitors
W. Bartolini (2006)
Carbamate derivatives of alkyl heterocycles, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Abouabdellah (2010)
Preparation of aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
G. J. Breitenbucher (2010)
10.1124/jpet.110.175778
Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in Mice
S. Kinsey (2011)
10.1208/s12248-009-9110-7
Inhibitors of Endocannabinoid-Metabolizing Enzymes Reduce Precipitated Withdrawal Responses in THC-Dependent Mice
J. Schlosburg (2009)
Alkylcarbamic acid ester inhibitors of fatty acid amide hydrolase, and therapeutic use
O. Dasse (2007)
10.1021/jm101597x
Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics.
Cyrine Ezzili (2011)
10.1002/CBDV.200790159
The N‐Acylethanolamine‐Hydrolyzing Acid Amidase (NAAA)
K. Tsuboi (2007)
10.1021/JM021119G
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.
G. Tarzia (2003)
Inhibiting fatty acid amide normalizes endotoxin-induced enhanced gastrointestinal motility in the mouse
M Bashashati (2011)
4-[3- (Aryloxy)benzylidene]-3-methylpiperidine aryl carboxamide compounds useful as FAAH inhibitors and their preparation
M. J. Meyers (2009)
Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
C·胡尔纳尔特 (2008)
Preparation of phenylheteroaryloxadiazolylheptanone derivatives and analogs for use as FAAH inhibitors
D. L. Boger (2010)
10.1038/sj.bjp.0706971
Lack of selectivity of URB602 for 2‐oleoylglycerol compared to anandamide hydrolysis in vitro
S. Vandevoorde (2007)
Ether benzylidene piperidine 5membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127943
L. K. Fay (2009)
Synthesis of COX-2 and FAAH inhibitors
W. Bartolini (2006)
10.1073/pnas.0806121105
Structure-guided inhibitor design for human FAAH by interspecies active site conversion
Mauro Mileni (2008)
10.1021/jm9012196
X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase.
Mauro Mileni (2010)
Preparation of piperidineboronic acid derivatives for use as fatty acid amide hydrolase inhibitors
A. C. Castro (2010)
10.1038/sj.bjp.0705608
Oleamide: a member of the endocannabinoid family?
C. Fowler (2004)
10.1074/jbc.M606646200
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals*
B. Q. Wei (2006)
10.1111/j.1476-5381.2011.01327.x
The endocannabinoid system and cancer: therapeutic implication
J. Guindon (2011)
Preparation of 7-azaspiro[3.5]nonane- 7-carboxamides as inhibitors of fatty acid amide hydrolase (FAAH)
S. A. Long (2010)
Azetidine derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof
S. Roughley (2009)
10.1016/j.neuropharm.2006.11.009
Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets
D. Zhang (2007)
10.1073/PNAS.97.10.5044
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.
D. Boger (2000)
Enol carbamate derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof
P. Minetti (2009)
10.1002/cmdc.200900137
Screening of Various Hormone‐Sensitive Lipase Inhibitors as Endocannabinoid‐Hydrolyzing Enzyme Inhibitors
Anna Minkkilae (2009)
10.1021/jm801042a
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
X. Wang (2009)
Methods and compositions related to targeting monoacylglycerol lipase
B. F. Cravatt (2010)
Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase
P. Minetti (2009)
Pyrazole derivatives useful as inhibitors of FAAH
L. S. Lin (2009)
10.1016/J.PLIPRES.2006.03.003
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
T. Sugiura (2006)
10.2174/156802610791164238
Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Anna Minkkilae (2010)
Azaspiranyl-alkylcarbamate derivatives of 5membered heterocycles, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Abouabdellah (2010)
10.1002/cbic.200800428
CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious MGL Assay
G. Muccioli (2008)
10.1146/ANNUREV.BIOCHEM.74.082803.133450
Structure and function of fatty acid amide hydrolase.
M. K. McKinney (2005)
10.1021/jm200723m
SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
Marion Feledziak (2011)
10.4172/2161-0444.S1.007
Inhibitors of fatty acid amide hydrolase (FAAH): SAR and results in pre-clinical pain models
J. Breitenbucher (2013)
N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
R. Apodaca (2007)
10.1021/BI990637Z
Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.
M. Patricelli (1999)
Preparation of piperazine-1carboxamide derivatives as brain/neuronal cell-protecting agents, and therapeutic agents for sleep disorder
T. Matsumoto (2007)
Preparation of oxazole derivatives as inhibitors of fatty acid amide hydrolase (FAAH)
D. L. Boger (2008)
10.1021/jm901891p
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
V. Onnis (2010)
10.1124/mol.110.068304
Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System
P. Chanda (2010)
10.1016/J.CHEMBIOL.2006.07.008
URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain.
S. Saario (2006)
10.1016/j.bbalip.2008.08.004
Amino acid residues crucial in pH regulation and proteolytic activation of N-acylethanolamine-hydrolyzing acid amidase.
J. Wang (2008)
10.1038/sj.bjp.0707425
The inhibition of monoacylglycerol lipase by URB602 showed an anti‐inflammatory and anti‐nociceptive effect in a murine model of acute inflammation
F. Comelli (2007)
10.1073/pnas.0909411106
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo
J. Z. Long (2009)
Preparation of benzoxazole compounds as FAAH modulators
C. Kaub (2010)
Indole derivatives as FAAH inhibitors and their preparation and use in the treatment of diseases
K. Sprott (2008)
Oxadiazole ketones as inhibitors of fatty acid amide hydrolase, their preparation, pharmaceutical compositions, and use in therapy
D. L. Boger (2006)
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
R. Apodaca (2008)
Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
C. M. Flores (2010)
4-[3- (Aryloxy)benzylidene]-3-methylpiperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation
M. J. Meyers (2009)
Alkyl, alkenyl and alkynyl carbamate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Almario-Garcia (2006)
10.1016/j.bbalip.2008.10.007
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo.
T. Bisogno (2009)
10.1016/j.chembiol.2008.06.008
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.
N. Zvonok (2008)
The MAGL Inhibitor, JZL184, Attenuates LiCl-Induced Vomiting in the Suncus murinus and 2AG Attenuates LiCl-Induced Nausea-Like Behavior in Rats
M. Sticht (2011)
10.1021/JM0340795
Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase.
S. Vandevoorde (2003)
10.1007/s11745-008-3217-y
Biological Functions and Metabolism of Oleoylethanolamide
C. Thabuis (2008)
10.1124/JPET.104.078980
Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation
D. Fegley (2005)
Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
A. Makriyannis (2009)
Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents WO2010101724
P. Liu (2010)
2-keto-oxazoles as modulators of fatty acid amide hydrolase
R. Apocada (2007)
10.1016/j.bmc.2009.11.028
1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
Laura Forster (2010)
Preparation of oxazole derivatives as fatty acid amide hydrolase inhibitors
D. L. Boger (2008)
10.1110/PS.9.12.2329
Structural comparison of Ntn‐hydrolases
C. Oinonen (2000)
Preparation of keto - oxazole compounds as modulators of fatty acid amide hydrolase
D. Boger (2007)
10.1016/J.CHEMBIOL.2007.11.006
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.
J. Blankman (2007)
10.1021/BI0608008
A FAAH-regulated class of N-acyl taurines that activates TRP ion channels.
A. Saghatelian (2006)
10.1016/j.jpain.2010.04.001
Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.
S. Kinsey (2010)
10.1021/JM050977K
Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates.
G. Muccioli (2006)
10.1038/sj.bjp.0704767
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol
Tim C Kirkham (2002)
Preparation of substituted naphthyridines as FAAH modulators
M. G. Kelly (2009)
Preparation of aryl-hydroxyethylaminopyrimidines and triazines as modulators of fatty acid amide hydrolase
R. Apodaca (2009)
Preparation of imidazole derivatives useful as inhibitors of FAAH
L. S. Lin (2009)
10.1038/nm803
Modulation of anxiety through blockade of anandamide hydrolysis
S. Kathuria (2003)
Preparation of isoxazoline derivatives for use as fatty acid amide hydrolase inhibitors
M. L. Behnke (2010)
10.1021/jm9008532
beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase.
Marion Feledziak (2009)
Alkylthiazolyl carbamates, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Abouabdellah (2010)
Ether benzylidene piperidine aryl carboxamide compounds as FAAH inhibitors and their preparation
L. K. Fay (2009)
Ionizable inhibitors of fatty acid amide hydrolase WO2008020866
O. Dasse (2008)
Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors
L. K. Fay (2008)
10.1517/17460441.2010.513378
Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors
Hongfeng Deng (2010)
Metabolically stabilized inhibitors of fatty acid amide hydrolase, and use in the treatment of pain
O. Dasse (2008)
10.1021/jm800311k
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
M. Seierstad (2008)
10.1073/pnas.1016167108
Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)
X. Min (2011)
10.1016/S0006-2952(01)00712-2
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
C. Fowler (2001)
10.1016/j.chembiol.2010.08.013
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.
G. Godlewski (2010)
10.1074/jbc.M106261200
Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-inflammatory Substance*
N. Ueda (2001)
10.1124/MOL.104.002071
RNA Interference Suggests a Primary Role for Monoacylglycerol Lipase in the Degradation of the Endocannabinoid 2-Arachidonoylglycerol
T. Dinh (2004)
10.1038/384083A0
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
10.2174/1381612023395655
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications.
T. Bisogno (2002)
10.1016/j.bmcl.2009.11.134
Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.
C. Saturnino (2010)
Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
A. Abouabdellah (2006)
5-Membered heterocyclyl)alkyl 7azaspiro[3,5]nonane-7-carboxylate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies
A. Abouabdellah (2010)
10.1038/sj.bjp.0707456
The complications of promiscuity: endocannabinoid action and metabolism
S. Alexander (2007)



This paper is referenced by
NICOTINE AND METHYLPHENIDATE CHORNIC EXPOSURE ON ADULT CANNABINOID RECEPTOR AGONIST (CP 55,940) PLACE CONDITIONING IN MALE RATS
Christopher P Plant (2016)
10.1161/HYPERTENSIONAHA.114.03633
Increased Angiotensin II Contraction of the Uterine Artery at Early Gestation in a Transgenic Model of Hypertensive Pregnancy Is Reduced by Inhibition of Endocannabinoid Hydrolysis
V. Pulgar (2014)
10.1016/j.bmc.2015.03.033
1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase: Effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability.
Tom R Sundermann (2015)
10.1016/B978-0-12-800213-1.00065-1
Chapter 65 – Cannabinoid Agonists
A. Bagues (2016)
10.1021/bi400430k
Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry study.
I. Karageorgos (2013)
10.2174/1381612820666140130212957
Role of the endocannabinoid system in the neuroendocrine responses to inflammation.
A. de Laurentiis (2014)
10.1016/B978-0-12-417041-4.00024-2
The ever-expanding world of the endocannabinoids: A concise introduction
F. Piscitelli (2015)
10.1016/j.ejmech.2013.02.005
Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: modulation at the N-portion and distal phenyl ring.
G. Ortar (2013)
10.1038/nrd.2018.115
New approaches and challenges to targeting the endocannabinoid system
V. Marzo (2018)
10.1038/s41398-018-0141-7
Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors
Gaurav Bedse (2018)
10.1007/7653_2018_11
In Vitro Evaluation of Serine Hydrolase Inhibitors
C. Pope (2018)
10.1016/j.euroneuro.2015.02.005
The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—A practical view
C. Fowler (2015)
10.1016/j.neulet.2020.134900
Influence of cannabinoids upon nerve-evoked skeletal muscle contraction
D. Ge (2020)
10.1016/j.pain.2013.03.023
Endocannabinoids: A unique opportunity to develop multitarget analgesics
S. Maione (2013)
10.31887/DCNS.2020.22.3/fthibaut
Cannabinoids: for better and for worse

Florence Thibaut (2020)
Role(s) of the mitochondrial type-1 cannabinoid receptor in the brain
Tifany Desprez (2015)
10.1016/j.ejmech.2012.11.035
An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH).
Marion Feledziak (2013)
10.1073/pnas.1524589113
α/β-Hydrolase domain-containing 6 (ABHD6) negatively regulates the surface delivery and synaptic function of AMPA receptors
Mengping Wei (2016)
10.1016/j.bioorg.2019.103353
Modification on the 1,2-dihydro-2-oxo-pyridine-3-carboxamide core to obtain multi-target modulators of endocannabinoid system.
F. Gado (2019)
10.2217/cnc-2017-0010
Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion
M. B. Elliott (2017)
10.1016/j.bbalip.2017.01.001
N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Mireille Alhouayek (2017)
10.1016/j.bmc.2016.12.042
Development of new inhibitors for N-acylethanolamine-hydrolyzing acid amidase as promising tool against bladder cancer.
R. Vago (2017)
10.1016/j.chembiol.2012.05.001
Discrimination between two endocannabinoids.
N. Ueda (2012)
The role of FAAH and MAGL inhibitors in anxiety disorders
Magdalena Burat (2020)
10.1107/S2053230X19002152
Pseudomonas aeruginosa esterase PA2949, a bacterial homolog of the human membrane esterase ABHD6: expression, purification and crystallization
Florian Bleffert (2019)
10.1002/cmdc.201402374
O‐(Triazolyl)methyl Carbamates as a Novel and Potent Class of Fatty Acid Amide Hydrolase (FAAH) Inhibitors
Giampiero Colombano (2015)
10.1098/rstb.2011.0382
Why do cannabinoid receptors have more than one endogenous ligand?
V. Di Marzo (2012)
10.1002/cmdc.201402453
Optimization of 1,2,5‐Thiadiazole Carbamates as Potent and Selective ABHD6 Inhibitors
Jayendra Z Patel (2015)
10.2174/1871524911313010010
Brain molecules and appetite: the case of oleoylethanolamide.
Andrea Sarro-Ramírez (2013)
10.1016/j.bmcl.2016.05.001
The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.
J. Keith (2016)
10.1002/cmdc.201500395
A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation
R. Scarpelli (2016)
10.1021/jm400923s
Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.
Jayendra Z Patel (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar